SrasV1, PubMed, Curation, bibRecord, 001496

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.

Identifieur interne : 001496 ( PubMed/Curation ); précédent : 001495; suivant : 001497

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.

Auteurs : Ye V. Liu [États-Unis] ; Michael J. Massare ; Dale L. Barnard ; Thomas Kort ; Margret Nathan ; Lei Wang ; Gale Smith

Source :

Vaccine [ 1873-2518 ] ; 2011.

RBID : pubmed:21762752

Descripteurs français

English descriptors

KwdEn :
- Adjuvants, Immunologic (administration & dosage), Aluminum Hydroxide (administration & dosage), Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Baculoviridae (genetics), Body Weight, Disease Models, Animal, Female, Genetic Vectors, Insecta, Lung (virology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Membrane Glycoproteins (metabolism), Mice, Mice, Inbred BALB C, Protein Multimerization, Recombinant Proteins (genetics), Recombinant Proteins (immunology), Recombinant Proteins (metabolism), Rodent Diseases (prevention & control), SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Survival Analysis, Vaccines, Virosome (genetics), Vaccines, Virosome (immunology), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Envelope Proteins (metabolism), Viral Load, Viral Matrix Proteins (genetics), Viral Matrix Proteins (metabolism), Viral Vaccines (genetics), Viral Vaccines (immunology).
MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Aluminum Hydroxide.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- genetics : Baculoviridae, Membrane Glycoproteins, Recombinant Proteins, SARS Virus, Vaccines, Virosome, Viral Envelope Proteins, Viral Matrix Proteins, Viral Vaccines.
- chemical , immunology : Membrane Glycoproteins, Recombinant Proteins, SARS Virus, Vaccines, Virosome, Viral Envelope Proteins, Viral Vaccines.
- chemical , metabolism : Membrane Glycoproteins, Recombinant Proteins, Viral Envelope Proteins, Viral Matrix Proteins.
- prevention & control : Rodent Diseases, Severe Acute Respiratory Syndrome.
- virology : Lung.
- Animals, Body Weight, Disease Models, Animal, Female, Genetic Vectors, Insecta, Mice, Mice, Inbred BALB C, Protein Multimerization, Spike Glycoprotein, Coronavirus, Survival Analysis, Viral Load.

Abstract

SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents.

DOI: 10.1016/j.vaccine.2011.06.111
PubMed: 21762752

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001496

Links to Exploration step

pubmed:21762752

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.</title>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V" last="Liu">Ye V. Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Novavax Inc., 9920 Belward Campus Drive, Rockville, MD 20850, United States. yliu@novavax.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax Inc., 9920 Belward Campus Drive, Rockville, MD 20850</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Massare, Michael J" sort="Massare, Michael J" uniqKey="Massare M" first="Michael J" last="Massare">Michael J. Massare</name>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name>
</author>
<author><name sortKey="Kort, Thomas" sort="Kort, Thomas" uniqKey="Kort T" first="Thomas" last="Kort">Thomas Kort</name>
</author>
<author><name sortKey="Nathan, Margret" sort="Nathan, Margret" uniqKey="Nathan M" first="Margret" last="Nathan">Margret Nathan</name>
</author>
<author><name sortKey="Wang, Lei" sort="Wang, Lei" uniqKey="Wang L" first="Lei" last="Wang">Lei Wang</name>
</author>
<author><name sortKey="Smith, Gale" sort="Smith, Gale" uniqKey="Smith G" first="Gale" last="Smith">Gale Smith</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21762752</idno>
<idno type="pmid">21762752</idno>
<idno type="doi">10.1016/j.vaccine.2011.06.111</idno>
<idno type="wicri:Area/PubMed/Corpus">001496</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001496</idno>
<idno type="wicri:Area/PubMed/Curation">001496</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001496</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.</title>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V" last="Liu">Ye V. Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Novavax Inc., 9920 Belward Campus Drive, Rockville, MD 20850, United States. yliu@novavax.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax Inc., 9920 Belward Campus Drive, Rockville, MD 20850</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Massare, Michael J" sort="Massare, Michael J" uniqKey="Massare M" first="Michael J" last="Massare">Michael J. Massare</name>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name>
</author>
<author><name sortKey="Kort, Thomas" sort="Kort, Thomas" uniqKey="Kort T" first="Thomas" last="Kort">Thomas Kort</name>
</author>
<author><name sortKey="Nathan, Margret" sort="Nathan, Margret" uniqKey="Nathan M" first="Margret" last="Nathan">Margret Nathan</name>
</author>
<author><name sortKey="Wang, Lei" sort="Wang, Lei" uniqKey="Wang L" first="Lei" last="Wang">Lei Wang</name>
</author>
<author><name sortKey="Smith, Gale" sort="Smith, Gale" uniqKey="Smith G" first="Gale" last="Smith">Gale Smith</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Aluminum Hydroxide (administration & dosage)</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Baculoviridae (genetics)</term>
<term>Body Weight</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Genetic Vectors</term>
<term>Insecta</term>
<term>Lung (virology)</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Membrane Glycoproteins (metabolism)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Protein Multimerization</term>
<term>Recombinant Proteins (genetics)</term>
<term>Recombinant Proteins (immunology)</term>
<term>Recombinant Proteins (metabolism)</term>
<term>Rodent Diseases (prevention & control)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Survival Analysis</term>
<term>Vaccines, Virosome (genetics)</term>
<term>Vaccines, Virosome (immunology)</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Envelope Proteins (metabolism)</term>
<term>Viral Load</term>
<term>Viral Matrix Proteins (genetics)</term>
<term>Viral Matrix Proteins (metabolism)</term>
<term>Viral Vaccines (genetics)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Analyse de survie</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Anticorps neutralisants (sang)</term>
<term>Baculoviridae (génétique)</term>
<term>Charge virale</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (génétique)</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Glycoprotéines membranaires (métabolisme)</term>
<term>Hydroxyde d'aluminium (administration et posologie)</term>
<term>Maladies des rongeurs ()</term>
<term>Modèles animaux de maladie humaine</term>
<term>Multimérisation de protéines</term>
<term>Poids du corps</term>
<term>Poumon (virologie)</term>
<term>Protéines de l'enveloppe virale (génétique)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Protéines de l'enveloppe virale (métabolisme)</term>
<term>Protéines de la matrice virale (génétique)</term>
<term>Protéines de la matrice virale (métabolisme)</term>
<term>Protéines recombinantes (génétique)</term>
<term>Protéines recombinantes (immunologie)</term>
<term>Protéines recombinantes (métabolisme)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins à virosomes (génétique)</term>
<term>Vaccins à virosomes (immunologie)</term>
<term>Vecteurs génétiques</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Aluminum Hydroxide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Hydroxyde d'aluminium</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Baculoviridae</term>
<term>Membrane Glycoproteins</term>
<term>Recombinant Proteins</term>
<term>SARS Virus</term>
<term>Vaccines, Virosome</term>
<term>Viral Envelope Proteins</term>
<term>Viral Matrix Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Baculoviridae</term>
<term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Protéines de la matrice virale</term>
<term>Protéines recombinantes</term>
<term>Vaccins antiviraux</term>
<term>Vaccins à virosomes</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Protéines recombinantes</term>
<term>Vaccins antiviraux</term>
<term>Vaccins à virosomes</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Recombinant Proteins</term>
<term>SARS Virus</term>
<term>Vaccines, Virosome</term>
<term>Viral Envelope Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Recombinant Proteins</term>
<term>Viral Envelope Proteins</term>
<term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Protéines de la matrice virale</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Rodent Diseases</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Body Weight</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Genetic Vectors</term>
<term>Insecta</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Protein Multimerization</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Survival Analysis</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term>
<term>Animaux</term>
<term>Charge virale</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Maladies des rongeurs</term>
<term>Modèles animaux de maladie humaine</term>
<term>Multimérisation de protéines</term>
<term>Poids du corps</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vecteurs génétiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21762752</PMID>
<DateCompleted><Year>2011</Year>
<Month>12</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>29</Volume>
<Issue>38</Issue>
<PubDate><Year>2011</Year>
<Month>Sep</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.</ArticleTitle>
<Pagination><MedlinePgn>6606-13</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2011.06.111</ELocationID>
<Abstract><AbstractText>SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents.</AbstractText>
<CopyrightInformation>Copyright © 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Ye V</ForeName>
<Initials>YV</Initials>
<AffiliationInfo><Affiliation>Novavax Inc., 9920 Belward Campus Drive, Rockville, MD 20850, United States. yliu@novavax.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Massare</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Barnard</LastName>
<ForeName>Dale L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kort</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nathan</LastName>
<ForeName>Margret</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Lei</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Smith</LastName>
<ForeName>Gale</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>U01 AI061988-02</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>1U03AI06198801</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U01 AI061988-01</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01-AI-15345</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U01 AI061988-03</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>07</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C488936">M1 protein, Influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022721">Vaccines, Virosome</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5QB0T2IUN0</RegistryNumber>
<NameOfSubstance UI="D000536">Aluminum Hydroxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000536" MajorTopicYN="N">Aluminum Hydroxide</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016367" MajorTopicYN="N">Baculoviridae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007313" MajorTopicYN="N">Insecta</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012376" MajorTopicYN="N">Rodent Diseases</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D022721" MajorTopicYN="N">Vaccines, Virosome</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year>
<Month>02</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2011</Year>
<Month>03</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2011</Year>
<Month>06</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>7</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>7</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>12</Month>
<Day>13</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21762752</ArticleId>
<ArticleId IdType="pii">S0264-410X(11)01005-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2011.06.111</ArticleId>
<ArticleId IdType="pmc">PMC3165014</ArticleId>
<ArticleId IdType="mid">NIHMS313706</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Trop Med Int Health. 2009 Nov;14 Suppl 1:36-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19508440</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Immunol. 2008 Feb;45(4):868-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17905435</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trop Med Int Health. 2009 Nov;14 Suppl 1:85-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19508435</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2007 May 10;25(19):3871-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17337102</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2006 Feb 13;24(7):1028-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16388880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Nov;79(22):13848-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16254320</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2006 Apr 24;24(17):3624-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16497416</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2007 Aug 21;25(34):6334-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17640780</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arch Virol. 2010 Apr;155(4):507-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20217155</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Cell Biol. 2010 Jul 26;190(2):187-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20660627</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Biotechnol. 2007 Dec;18(6):537-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18083549</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 1967 Apr;1(2):175-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4293939</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2010 Aug 2;28(34):5524-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20600506</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Microbes Infect. 2005 May;7(5-6):882-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15878679</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2006 Jan 30;24(5):652-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16214268</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2008 Feb 6;26(6):797-808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18191004</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2008 Jul 16;3(7):e2685</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18628832</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>DNA Cell Biol. 2006 Dec;25(12):668-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17184168</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunology. 2007 Dec;122(4):496-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17680799</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2004 Oct 8;576(1-2):174-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474033</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pathol. 2004 Jun;203(2):622-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15141376</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Methods. 2006 Sep;40(1):60-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16997714</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2009 Jul;8(7):887-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19538115</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Virus Res. 2006;66:193-292</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16877062</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2009 Dec 20;395(2):210-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19853271</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Int J Tuberc Lung Dis. 2003 Dec;7(12):1117-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14677886</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 11;318(4):833-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15147946</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pathol. 2004 Jun;203(2):631-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2011 Oct 13;29(44):7826-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21816199</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immune Based Ther Vaccines. 2010 Sep 13;8:5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20836885</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunology. 2010 Jun;130(2):254-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20406307</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin. 2008 Jan-Feb;4(1):5-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18438104</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Apr 10;334(2):160-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15780866</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12557-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507643</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Int J Antimicrob Agents. 2010 Nov;36 Suppl 1:S21-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20801001</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Jun;35(6):587-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12796822</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2010 Jul 5;28(30):4771-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20470801</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2007 Mar 8;25(12):2173-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17227689</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):45-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17416434</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2008 Jan 30;3(1):e1501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18231588</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Immunol. 2007;25:443-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17243893</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2008 Nov 25;26(50):6338-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18824060</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001496 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001496 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:21762752
   |texte=   Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:21762752" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki